Form 4: Champions Oncology Director Acquires Options in Company Stock

Philip P. Breitfeld, a director at Champions Oncology, Inc., has acquired options to purchase 18,715 shares of common stock.

Summary

• Philip P. Breitfeld, a director of Champions Oncology, Inc., has reported the acquisition of options to purchase 18,715 shares of the company's common stock.
• The options were granted on November 12, 2024, at an exercise price of $4.64 per share.
• These options vest over a twelve-month period, with vesting dates on November 12, 2024, February 12, 2025, May 12, 2025, and August 12, 2025.
• The options expire on November 12, 2034.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction, indicating neither strong positive nor negative sentiment. It's a standard part of director compensation.

Positives

• The acquisition of options by a director may indicate confidence in the company's future performance.

Industry Context

This is a standard transaction for company directors, often used as part of their compensation package and to align their interests with those of shareholders.

Comparison to Industry Standards

• Option grants to directors are a common practice across the biotechnology and pharmaceutical industries, often used as a form of incentive compensation.
• The vesting schedule of 12 months is fairly standard for such grants.
• The exercise price of $4.64 is specific to Champions Oncology's stock price at the time of the grant.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates a director's belief in the company's future.

Key Dates

Keywords

Champions Oncology, Director, Options, Stock Options, Beneficial Ownership, SEC Form 4, CSBR